Kornimate/medical-research-clean huggingface dataset:
the effect of micro fragmented adipose tissue (mfat) on shoulder osteoarthritis

Conditions: Osteoarthritis Shoulder; Shoulder Pain

Summary: this is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with intra-articular injection of micro fragmented adipose tissue versus conventional therapy of intra-articular injection of corticosteroid.

this study will be a randomized controlled trial to compare outcomes between intra-articular injection of micro fragmented adipose tissue and intra-articular injection of corticosteroid in patients with mild to moderate osteoarthritis of the shoulder. micro fragmented adipose tissue will be harvested at the subcutaneous tissue by lipoaspiration. once fat tissue is obtained, it will be processed with minimal manipulation in the clinic room. to be considered for participation in this study, patients must have radiographic evidence of mild to moderate osteoarthritis of the shoulder (glenohumeral joint). in addition, patients must meet several inclusion/exclusion criteria to be randomized and included in this study.

Eligibility criteria:
inclusion criteria: * age between 25 and 75 years-old * diagnosis of pre-existing osteoarthritis of the glenohumeral joint * working understanding of the english language and able to fully understand the procedure * capable of providing informed consent * able to complete online, in-person or phone surveys for the purposes of follow-up * capable of understanding pre- and post-procedure care instructions * ambulatory at baseline * previous trial and failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and/or injections. exclusion criteria: * age \ 75 years old * radiographs demonstrating either no, little osteoarthritis, severe(bone on bone) osteoarthritis * prior total or partial joint replacement surgery or surgery involving cartilage regeneration * previous cortisone, prp or hyaluronic acid intra-articular injection within the last 3 months * co-morbidity with the rheumatologic condition, inflammatory arthritis * currently undergoing immunomodulatory therapy * uncontrolled endocrine disorder * bmi \>40 or joint space not visible by ultrasound * current diagnosis of osteomyelitis, human immunodeficiency virus (hiv-1, -2) and/or hepatitis c (hcv), infection, and poorly controlled diabetes (hga1c \>7.0) * pregnancy or planned pregnancy * previous stem cell injection into treatment joint * patient scheduled to undergo any concomitant shoulder surgical procedures or other surgery which may affect outcomes. * coagulopathy or anticoagulant treatment * chronic pain involving multiple body parts or opioid medication management * diagnosis of fibromyalgia * concomitant massive(2 tendons with retraction), complete rotator cuff tendon tear
copeptin in covid-19

Conditions: COVID-19

Summary: this study aimed to investigate the change in serum level of copeptin, a neuroendocrine biomarker, in differentiation between mild-moderate and severe covid-19 cases on admission time and to find its diagnostic potential.

this prospective study enrolled 160 individuals with confirmed covid-19 infection using pcr. they were recruited from al-zahraa hospital, faculty of medicine (girls), al-azhar university, cairo, egypt, which was specifically designated for the isolation of sars-cov-2 positive patients. according to the egyptian ministry of health and population's (mohp) recommendations, patients were divided into 80 mild-moderate covid-19 patients and 80 severe covid-19 patients. cases classified as mild-moderate fulfilled the following criteria: fever and respiratory symptoms, corad 1-5, and oxygen saturation (spo2 92 percent), while severe cases met the following criteria: fever and respiratory symptoms, corad 4-5, and oxygen saturation (spo2 92 percent). all participants or their corresponding companions signed a free informed consent form. the study was approved by the research ethics committee of al-azhar university's faculty of medicine (girls), cairo, egypt, with approval number (202106884), and adhered to the helsinki declaration's precepts. pregnancy, covid-19 patients with morbid obesity, cancer, or autoimmune disease, and those who took immunomodulators or initiated the covid-19 treatment programme were excluded. additionally, patients having a history of recurrent covid-19 infection were excluded from the study.

Eligibility criteria:
inclusion criteria: adult patients \> 18 years with the positive result of real-time reverse transcriptase-polymerase chain reaction assay (rt-pcr) for sars-cov-2 rna. severity stratification is based on the guidance of the egyptian moh protocol. exclusion criteria: pregnant covid-19 patients. covid-19 patients with morbid obesity, malignancy, autoimmune diseases and those who received immunomodulators or began covid-19 treatment protocol. also, patients with a history of recurrent covid-19 will be excluded.
behavioral exercise training for men undergoing androgen depr therapy for prostate ca

Conditions: Prostate Cancer

Summary: to refine a remote behavioral exercise training intervention for testing in a larger randomized trial.

determine feasibility of recruiting a sample of medically underserved prostate cancer patients undergoing treatment with androgen deprivation therapy (adt) to a remotely delivered (i.e., home-based) exercise intervention and determine the interventions acceptability.

Eligibility criteria:
inclusion criteria: to be eligible men, transwomen or non-binary individuals must meet the following criteria: * be diagnosed with stage ii/iii/iv prostate cancer * be currently undergoing treatment with adt (intermittent or prolonged) * have completed local curative-intent treatment, including prostatectomy or definitive radiation * be \>40 years of age if non-hispanic black or rural dwelling; otherwise \>60 years of age up to 85 * be willing to give an informed consent and sign a hipaa authorization form * not have any hearing or sight impairments that result in the inability to use the telephone or hear normal conversation * must be able to join an intervention group by personal computer, smartphone or telephone call and should agree to recording of an interview * be without any serious medical condition that precludes safe participation in an exercise program * speak english. * meet protocol definition of medically underserved: which is consider medically underserved patients to be a) older men (\>75 years), b) men who live in rural zip code areas, or c) men who identify as being non-hispanic black. they may also be at the intersectionality of these groups (i.e., older black men living in a rural zip code area).

Keywords: exercise prostate cancer androgen deprivation therapy (adt) home based exercise intervention
ge healthcare volumerad lung nodule detection study

Conditions: Pulmonary Nodule, Solitary; Multiple Pulmonary Nodules

Summary: to perform a multiple reader, multiple case (mrmc) observer study assessing the detection performance of volumerad tomosynthesis of the chest in detecting lung nodules.

digital tomosynthesis is a form of limited angle tomography that creates a series of section images using a conventional x-ray tube and generator, a digital detector, and appropriate reconstruction software. it creates section images from a series of projection images acquired as the x-ray tube moves along a prescribed path. because tomosynthesis can minimize the visual presence of overlying anatomy - the ribs, for example - it has the potential to improve the detection of lesions such as pulmonary nodules when compared with conventional chest radiography. the primary aim of this study is to determine whether the use of volumerad tomosynthesis, in addition to cxr, increases physician accuracy in the detection of lung nodules between 3mm and 20mm in diameter when compared to conventional posterior-anterior (pa) and lateral (lat) chest radiography (cxr). this aim will be addressed by measuring free-response performance of experienced (with volumerad), blinded expert readers' detection performance. specifically, we will compare detection performance, as measured by the area under the alternative free response receiver operating characteristic (afroc) curve, among readers viewing pa and lat chest x-rays versus volumerad tomosynthesis. the nodule will be the unit of analysis.

Eligibility criteria:
inclusion criteria: * scheduled for chest ct as part of their needed medical care; * if available, individuals who have had previous imaging to suggest they fulfill the needs of the study; * 18 years of age, or older; * in good enough physical condition to stand motionless and hold their breath during the image acquisition procedures. exclusion criteria: * children under 18 years of age; * women who are pregnant or who suspect they may be pregnant; * individuals who on previous imaging are shown to have objects in or around the lungs that might produce substantial artifacts that would obscure pulmonary nodules; * individuals who on recent imaging had active lung or pleural disease that would obscure pulmonary nodules; * individuals with more than 5 pulmonary nodules between 5mm and 20mm in diameter in either right or left lung. * individuals suspected to have more than 15 total nodules between 3mm and 20mm. note that up to 20 nodules between 3mm and 20mm will be allowed in the final study sample.

Keywords: pulmonary nodule, solitary multiple pulmonary nodules
food supplements based on nettle and peppermint to control signs and symptoms induced by cancer therapies

Conditions: Breast Cancer; Gynecologic Cancer

Summary: the main purpose of this study is to evaluate the impact of food supplements (herbal remedies) on sign and symptoms induced by cancer therapies: nettle will be administered for improvement of anemia and fatigue; peppermint will be administered for improvement of nausea. secondary aims of the trial are to evaluate the impact of these supplements on the quality of life and to evaluate their tolerability profile.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years * karnofsky performance scale (kps) ≥ 90% * breast or gynecological cancer * informed consent signed before every procedure study specific, on day 1 of therapy cycle * inclusion criteria arm 1: presence of grade 1 anemia as per ctcae 4.0 criteria; patients on treatment with anti-cdk 4/6 or parp inhibitors or in adjuvant therapy with hormone therapy * inclusion criteria arm 2: presence of fatigue of any grade; patients on treatment with epirubicin and cyclophosphamide or carboplatin and taxane * inclusion criteria arm 3: presence of nausea of any grade, without vomiting; patients on treatment with epirubicin and cyclophosphamide or carboplatin and taxane exclusion criteria: * arm 1, 2 and 3: previous intake of food supplements within 4 weeks from the enrollment * arm 2: patients with evidence of anxiety or anxious-depressive syndrome; clinical hypothyroidism not compensated by replacement therapy; persistent insomnia * arm 3: patients with evidence of anxiety or anxious-depressive syndrome

Keywords: breast cancer ovarian cancer stinging nettle peppermint anemia fatigue nausea
comparison of mulligan mobilization technique and mckenzie exercises among patient with sacroilliac joint dysfunction

Conditions: Sacroiliac Joint Somatic Dysfunction

Summary: comparison of mulligan mobilization technique and mckenzie exercises among patient with sacroilliac joint dysfunction

to determine comparison of mulligan mobilization technique and mckenzie exercises in patient with sacroiliac joint dysfunction.

Eligibility criteria:
inclusion criteria: * age between 18 to 65.(29) * both male and female and pain in low back. (17) * pain in sacroiliac joint (psis) with or without radiating to buttocks.(30) * with acute/subacute pain within 4-12 weeks of onset and at least three of four clinical tests positive.(14) exclusion criteria: * midline pain in back, lumber stenosis, lumber radiculopathy, spondylolisthesis, disc related pain, pregnant females with sijd(29),any lower limb pathology or hip fracture, rheumatoid arthritis(17) * history of any orthopedic surgery, and conditions such as ankylosing spondylitis.(14) * spinal leminectomy * arthodesis
treatment of low bone density in cystic fibrosis.

Conditions: Osteoporosis; Cystic Fibrosis

Summary: cystic fibrosis (cf) -- an autosomal recessive genetic disease affecting about 60,000 individuals worldwide, including about 3,800 in italy -- is often associated with low bone mineral mass. the current aggressive therapies have ensured a much longer survival of cf patients but this has led to a higher frequency of osteoporosis and bone fractures, a serious problem which not only affects quality of life, but also hinders further therapeutic measures. the aim of this study, conducted on a large group of children, adolescents and young adults with cf, has been the evaluation of bone mass changes after 1 year of a simple treatment with rda-adjusted dietary calcium plus 25-oh vitamin d supplementation, and the feasibility and efficacy of alendronate treatment (for another year) in patients not responding to calcium + 25-oh vitamin d alone.

the study included 2 phases. phase 1 (1-year open-label observational study): following baseline evaluation, bone mass changes have been studied with a simple therapy of adequate calcium intake and 25-oh vitamin d supplements in all eligible subjects (n=171). phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study): the 128 subjects showing an insufficient response to calcium + 25-oh vitamin d alone (bone mass increase \<5%) at the end of phase 1, were randomized into 2 groups and assigned to alendronate treatment (n=65) or placebo (n=63) (in addition to calcium and 25-oh vitamin d as during phase 1). the study has been carried out by the coordinator's institution (istituto auxologico italiano)in collaboration with most regional reference centers for cf in italy.

Eligibility criteria:
inclusion criteria: * age 2-30 years * clinically stable condition * regular menses in females * low bone mineral apparent density for age (defined as bmad z-score ≤-2.0 if age ≤18 years or ≤-2.5 if age \>18 years). exclusion criteria: * two or more episodes of hypercalcemia and/or hypercalciuria * contraindications to 25-oh vitamin d or alendronate treatment * recent transplantation * other diseases or medications (glucocorticoids excepted) associated with bone loss.

Keywords: cystic fibrosis children adolescents low bone mass osteoporosis alendronate fractures
the hypotensive effect of propofol: an observational study

Conditions: Hypotension; Anesthesia

Summary: hypotension is a recognized frequent complication of induction of anesthesia. the intent of this research is to determine the incidence of hypotension in patients receiving anesthetic induction with propofol. this investigation seeks to examine how normal clinical practice or a "real world" understanding of the usual response to propofol affects hemodynamics without isolating or standardizing other variables. the current research concerns hypotension in normal clinical practice where variability exists. this project aims to gather information and data in an attempt to form a foundation upon which each of the other variables affecting blood pressure may be subsequently assessed.


Eligibility criteria:
inclusion criteria: * all asa 1-3 patients who are to receive propofol induction for general anesthesia exclusion criteria: * allergy to propofol * asa 4 and above

Keywords: propofol induction hypotension general population
a study evaluating the pf-03084014 in combination with docetaxel in patients with advanced breast cancer

Conditions: Breast Cancer Metastatic

Summary: this study is aimed to determine the tolerability of the pf-03084014 plus docetaxel combination in patients with advanced breast cancer. preliminary information about the efficacy of the combination will also be collected.


Eligibility criteria:
inclusion criteria: * diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease. exclusion criteria: * prior treatment with a gamma secretase inhibitors or other notch signaling inhibitors.

Keywords: breast cancer metastatic docetaxel pf-03084014
prevalence of delirium in patients undergoing cardiac surgery

Conditions: Heart Disease

Summary: the objective of this study is to determine prevalence of postoperative delirium and confusion in patients undergoing cardiac surgery. this proposal is a pilot study designed to evaluate effect of cardiac surgery on prevalence of delirium and confusion. the primary aim is to evaluate prevalence of delirium and confusion in patients undergoing cardiac surgery and to determine risk factors for this condition. a secondary aim is to evaluate organic brain injury by early postoperative diffusion weighted magnetic resonance imaging (dw-mri) in patients who develop delirium and confusion. the hypothesis to be tested is that patients with postoperative delirium and confusion have high incidence of organic brain injury as detected by dw-mri.


Eligibility criteria:
inclusion criteria: * all patients undergoing cardiac surgery in our institute in 2 year period * signed informed consent exclusion criteria: * past history of transient ischemic attacks, stroke, symptomatic carotid artery disease. * past history of psychiatric disorders * history of alcohol and drug abuse * history of severe kidney or liver disease (creatinine \>2.5mg/dl and bilirubin \> 2mg/dl) * known contraindications to mri

Keywords: delirium, confusion, cardiac surgery, organic brain injury, diffusion weighted magnetic resonance imaging (dw-mri)
metal ion release from an fda-approved metal-on-metal total hip replacement implant

Conditions: Non-inflammatory Degenerative Joint Disease

Summary: this is a multi-center, randomized study to compare blood and urine cobalt, chromium, and titanium ion levels of a metal-on-metal articular bearing coupled with two different head sizes to that of a conventional metal-on-polyethylene bearing.


Eligibility criteria:
inclusion criteria: * undergoing cementless primary total hip replacement * receiving acetabular cup of 52mm or greater * preoperative level of function and pain same as for conventional hip replacement * likelihood of obtaining relief of pain and improved function * full skeletal maturity * ability to follow instructions * good general health * willing to return for follow-up evaluations * x-ray evaluation confirming the presence of nidjd * femoral and acetabular bone stock that is sufficient, regarding strength and shape, and suitable to receive the implants exclusion criteria: * age less than 40 years or greater than 80 years at time of surgery * patients templated to receive an acetabular component smaller than 52mm in diameter * presence of a previous prosthetic hip replacement device in the hip joint to be operated * previous girdlestone procedure or surgical fusion of the hip to be operated * acute femoral neck fracture * above knee amputation of the contralateral and/or ipsilateral leg * patients with a diagnosis of inflammatory degenerative arthritis * skeletally immature * evidence of active infections that may spread to other areas of the body * the presence of a highly communicable disease that may limit follow-up * presence of known active metastatic or neoplastic disease * significant neurologic or musculoskeletal disorders or disease that may adversely affect gait or weightbearing * any previous hip surgery or conditions that may interfere with the total hip replacement's survival or outcome * any patient believed to be unwilling or unable to comply with a rehabilitation program for a cementless total hip replacement or indicates difficulty to return for follow-up * patient is know to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser * any patient who qualifies for inclusion in the study but refuses consent to participate in the study * any steroid therapy, local or systemic, within three months prior to surgery * patient requiring structural bone grafts in order to support the prosthetic components or to shape the bone to receive the implants * patient has known allergies to metal, e.g., jewelry * any patient not meeting all radiographic and clinical parameters for inclusion

Keywords: total hip replacement primary cementless total hip arthroplasty metal ion metal-on-metal
boceprevir (sch 503034) plus peg-intron, with and without added ribavirin, in patients with chronic hepatitis c, genotype 1, who did not respond to previous treatment with peginterferon alfa plus ribavirin (study p03659am2)(completed)

Conditions: Chronic Hepatitis C

Summary: the primary objective of this study is to determine the safe and effective dose range of boceprevir (sch 503034) in combination with peg-intron in adult subjects who have chronic hepatitis c without cirrhosis, and who have failed an adequate course of combination therapy with peginterferon-alfa plus ribavirin. a secondary objective is to explore whether ribavirin provides an additional benefit when combined with peg-intron plus boceprevir.


Eligibility criteria:
key inclusion criteria: * documented infection with chronic hepatitis c (chc), genotype 1. * documented failure to respond to an adequate course of treatment (minimum 12 weeks) with peginterferon-alfa plus ribavirin (failure defined as \<2 log drop in hcv-rna after 12 weeks of therapy or those who never become hepatitis c virus ribonucleic acid (hcv)-rna negative) * no evidence of cirrhosis on liver biopsy. * results of physical examination and laboratory tests within specified ranges. * abstinence from use of abused substances. key exclusion criteria: * women who are pregnant or nursing a child. * patients with cirrhosis, co-infection with hepatitis b or human immunodeficiency virus (hiv), and african-american patients (by protocol amendment 2, african-american patients can enroll). * previous treatment with any hepatitis c virus (hcv) polymerase or protease inhibitor. * patients who relapsed following response to previous treatment. * evidence of advanced liver disease, or liver disease from a cause other than chc. * pre-existing psychiatric condition.

Keywords: peg-intron ribavirin protease inhibitor